27 August 2026 Turkish regulators are investigating the drugmaker over its efforts to protect its drug from generic rivals—conduct that may sound familiar to European competition watchers.
24 August 2026
More News
21 August 2026 Under the terms of the agreement, which resolves all patent litigation between the biopharma rivals, Teva now has a launch date for its own version of Aurinia's Lupkynis.
20 August 2026 Three disputed sequencing patents took the spotlight as the Federal Circuit weighed challenges to a trio of PTAB rulings.
20 August 2026 A reported deal with an Indian manufacturer could clear a path for a future generic launch as the Korean drugmaker leverages one of its biggest US products.
19 August 2026 Questions over braille on a generic sleep disorder drug label will face fresh scrutiny after an appeals court found fault with the FDA’s approach.
18 August 2026 The European court has backed Abbott in a dispute over glucose-monitoring technology, while offering guidance on a key added-matter issue.
18 August 2026 The new partner counts pharmaceuticals and life sciences among his specialisms and previously worked in-house at Sandoz.
17 August 2026 The IP advocacy group has turned to former USPTO acting director Coke Morgan Stewart as it enters what it calls a “new chapter”.
Latest Features
Pharma
Reflecting on decades of patent searching experience, senior scientist on the CAS IP Services team, David Saari, offers insights into the importance of a multidisciplinary approach in today's competitive IP landscape.
MedTech
A new UPC Court of Appeal ruling closes an important procedural gap, with significant implications for how in-house teams structure validity defences, manage litigation costs and prepare for appeals, says Florian Laus of Simmons & Simmons.
Pharma
Canada has firmly slammed the door on patenting methods of medical treatment—but the battle over what counts as a "medical method" is only just beginning. Scott MacKendrick of ROBIC examines a landmark decision that leaves the door ajar for future litigation over complex drug-dosing regimens.
Europe
Europe’s latest patent fee increases are modest at the EPO but include a rare steep hike in the UK, forcing applicants to reassess filing routes, portfolio value, and long-term cost strategies, say James Bell and Yelena Morozova.
Asia
The clash between one of India’s largest B2B marketplaces and the country’s drugs regulator challenges the “passive” position of such platforms with regards to allegedly unlawful pharmaceutical listings, says Aarti Aggarwal of Remfry & Sagar.
Europe
After an overwhelmingly positive Supreme Court ruling for companies working in AI, Rachel Free of CMS outlines the necessary practical steps for patent holders—including enforcement of the ‘black box’ tech, the ruling’s influence on the UPC, and how to manage related applications.
Americas
From public use and foreign sales to the challenges of proving infringement, plant patents present unique legal opportunities—and pitfalls—for the agricultural industry, explain Bree Vculek, Gaby Longsworth, and Robert Millonig of Sterne Kessler.
Europe
Traceability and transparency of training practices, and the value of bespoke tool, are among the key AI trends that will be shaped by legal and regulatory developments in 2026, write experts from Rouse.
Latest Events Videos
Americas
Integrating AI into patent workflows promises efficiency gains, but requires strict oversight regarding accuracy, ethics, and data security. This panel explores the practical realities of deploying AI tools responsibly while maintaining the high standards required in life sciences prosecution.
Americas
Is Brazil moving toward a more predictable patent system, or simply shifting risk? This session examines the far-reaching impact of the ADI 5529 ruling, analysing how the end of automatic patent term extensions is reshaping filing and enforcement strategies.
Regulation & Industry
The post-grant challenge landscape is intensifying on both sides of the Atlantic. This panel analyses recent developments in IPRs, PGRs, EPO oppositions, and the UPC, detailing strategies to simultaneously defend existing portfolios and clear competitive space.
Americas
Choosing between patent protection and trade secrets is a delicate balancing act, especially amid regulatory scrutiny and unpredictable patent office timelines. This session delves into the frontlines of IP strategy, offering practical guidance on when each protection mechanism serves best.
Get up-to-date information on all our publications and events
Get critical life sciences news direct to your inbox